Brookline Capital Management Forecasts NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Brookline Capital Management decreased their FY2027 earnings per share estimates for Intellia Therapeutics in a research report issued on Thursday, November 7th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of $21.07 per share for the year, down from their previous forecast of $22.05. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.21) per share.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. The firm's revenue was down 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.38) EPS.

Several other equities research analysts have also recently weighed in on the stock. Evercore ISI raised shares of Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Barclays cut their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating on the stock in a research note on Friday. Royal Bank of Canada reiterated an "outperform" rating and issued a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Friday. Finally, Chardan Capital decreased their price objective on shares of Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating for the company in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.33.

Intellia Therapeutics Trading Up 4.6 %

Shares of NASDAQ NTLA traded up $0.77 during mid-day trading on Monday, reaching $17.50. The company had a trading volume of 2,565,427 shares, compared to its average volume of 1,664,452. Intellia Therapeutics has a 52 week low of $13.95 and a 52 week high of $34.87. The business's 50-day moving average is $19.17 and its 200-day moving average is $22.23. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -3.22 and a beta of 1.81.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. ARK Investment Management LLC raised its position in shares of Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company's stock worth $251,849,000 after buying an additional 659,651 shares in the last quarter. Vanguard Group Inc. raised its holdings in Intellia Therapeutics by 8.9% during the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock valued at $250,168,000 after buying an additional 746,263 shares in the last quarter. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock worth $51,494,000 after purchasing an additional 371,189 shares during the period. Dimensional Fund Advisors LP lifted its position in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Intellia Therapeutics by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 364,306 shares of the company's stock valued at $8,153,000 after purchasing an additional 2,301 shares during the period. Institutional investors own 88.77% of the company's stock.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 3.20% of the stock is owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.